Smartee’s ChiNext Filing: Growth Meets Profit Pressure

Smartee DentiTech (Zhejiang Zhengya Dental Technology) has lodged its prospectus for a ChiNext IPO, looking to capitalise on its position as China’s second-largest clear aligner brand. Revenue grew from RMB 648 million in 2023 to RMB 938 million in 2025, a compound annual growth rate above 20%, underlining robust demand from the private dental networks that drive its distribution. Yet profitability has been choppy, with net profit swinging from RMB 136 million in 2023 to just RMB 44 million in 2024 before recovering to RMB 127 million in 2025.

The financial disclosure comes as the invisible orthodontic sector is being reshaped by volume‑based procurement (VBP) policy. A 2022 provincial‑level alliance procurement, covering 15 provinces, cut average listed prices for clear aligners by around 40%, and a second‑round VBP expansion is now unfolding. The 2026 renewal, led by Shaanxi province, extends to a larger coalition of regions and keeps clear aligners mandatory in the catalogue, with research analysts warning of further downward pricing pressure on manufacturers.

Adding to the risk profile, on 16 June Smartee and three co‑defendants were served with a patent infringement lawsuit by Hangzhou Shuyaqi, which seeks RMB 10 million in damages. The case, filed in the Beijing IP Court, drops a legal cloud over the IPO timetable and raises questions about the company’s intellectual property portfolio at a time when it is leaning heavily on marketing rather than R&D for growth.

How VBP 2.0 and a Patent Clash Could Reshape the IPO Story

Angelalign vs. Smartee vs. Align: The Domestic Duopoly Tightens

Market share data cited in the report shows Angelalign at 37.75%, Smartee at 28.26% and Align Technology (Invisalign) at 24.82%. Together, the two Chinese players command more than 66% of the market, confirming the substitution of imported products. Smartee’s growth has been propelled by private dental practices and equipment distributors, a channel less directly affected by the early VBP rounds that focused on public hospitals. However, the incoming VBP 2.0, which is effectively a nationwide procurement, may force all channels to converge on lower prices, threatening the gross margins that have funded Smartee’s aggressive sales push.

Why a Sales‑Heavy Formula Is Being Tested by VBP 2.0

Financials reveal a striking asymmetry: in 2025 Smartee spent RMB 247 million on selling expenses, 26.3% of revenue, up from a 32.0% peak in 2023. Advertising and promotion alone totalled RMB 87.4 million in 2025, with cumulative marketing outlays surpassing RMB 240 million over three years. By contrast, R&D spending in 2025 was just RMB 57.3 million, representing 6.1% of revenue — down from 9.0% in 2023. The IPO allocation crystallises the imbalance: RMB 283 million earmarked for marketing expansion versus RMB 122 million for R&D facility upgrades. In a market where value‑based procurement will increasingly reward cost efficiency over branding, a model that devotes more than twice the cash to sales than to innovation looks vulnerable.

The 10‑Million‑Yuan Patent Suit: A Signal of Deeper IP Weakness?

The lawsuit brought by Hangzhou Shuyaqi alleges patent infringement by Smartee, its Shanghai and Sichuan units, and a Beijing dental chain. While the sum claimed is modest relative to Smartee’s revenue, the timing is awkward for an IPO. Patent disputes in medical devices can delay regulatory approvals, spook investors and, if the ruling goes against the company, force design‑around efforts that erode differentiation. Combined with the declining R&D ratio, the suit may amplify doubts about Smartee’s ability to build a defensible technology moat.

What Investors and Competitors Need to Watch Now

  • For IPO‑focused investors: The VBP 2.0 procurement expansion in 2026 will directly determine Smartee’s gross margin trajectory; watch the Shaanxi‑led bidding rules closely. A deeper‑than‑expected price cut could quickly eat into the profit recovery seen in 2025.
  • For competing clear aligner makers: Smartee’s reliance on marketing spend means that if VBP prizes cost leadership, Angelalign — with potentially stronger R&D — may widen its gap. Align Technology may accelerate localisation to regain share.
  • For private dental groups: A more competitive supplier landscape under VBP 2.0 is likely to lower procurement costs, but clinic owners should still assess whether Smartee’s product differentiation holds up if R&D intensity continues to slide.

Risk & Opportunity Assessment

Commercial RiskHighSmartee faces a high‑stakes pricing squeeze as the expanded VBP 2.0 scheme forces deeper price cuts for clear aligners; with sales and marketing already consuming 26% of revenue, further compression could rapidly erode profitability.
Competitive RiskMediumAngelalign’s margin‑leading market share and potentially stronger R&D capabilities could give it an advantage under a price‑sensitive VBP environment, threatening Smartee’s ability to maintain its second‑place slot.
Regulatory RiskHighThe 2026 VBP renewal makes clear aligners a mandatory procurement category across an expanded coalition of provinces, effectively a national price‑cap mechanism that directly overrides Smartee’s current pricing autonomy.
Reputation RiskMediumThe active patent infringement lawsuit, with RMB 10 million being sought from Smartee and its partners, could undermine confidence among both dental professionals and end‑users if the IP dispute escalates or leads to adverse publicity.
Technology DisruptionMediumA declining R&D intensity (6.1% of revenue in 2025 vs 9.0% in 2023) combined with the IPO’s heavy marketing allocation risks leaving Smartee vulnerable to competitors with faster innovation cycles, particularly as materials and digital workflow evolve.
Commercial OpportunityMediumThe IPO proceeds, if managed effectively, could accelerate penetration of public hospital channels now opened by VBP, potentially turning the procurement reform into a volume driver if Smartee can adjust its cost structure.